Clinical trials: HF - Heart Failure
Heart Failure, Congestive
A Phase I/II Clinical Study of SK&F-105517-D in Japanese Patients With Chronic Heart Failure
The primary objective of this study is to evaluate the safety and tolerability of SK\&F-105517-D in japanese patients with chronic heart failure.
- Trial name
- NCT00742508
- Testing
- SK&F-105517-D 10 mg capsule, Carvedilol-immediate release (IR) 2.5 mg tablet, SK&F-105517-D 20 mg capsule
- Where
- 23 sites in Japan
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline
Tachyarrhythmias, Heart Failure
Safety and Clinical Performance of the Protecta ICD and CRT-D
The purpose of the study is two-fold. In Phase I (Protecta Clinical Study), system performance will be evaluated. In Phase II (PainFree SST), the inappropriate shock-free rate at one year of subjects implanted with a Medtronic…
- Conditions
- Tachyarrhythmias, Heart Failure, Ventricular Dysfunction
- Trial name
- NCT00982397
- Testing
- Protecta VR-ICD, Protecta DR-ICD or CRT-D
- Where
- 122 sites in United States, Austria and 19 more
- Volunteers
- 2,770 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure With Reduced Ejection Fraction
Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients
The purpose of this study is to assess the safety and tolerability of initiating LCZ696 in heart failure patients with reduced ejection fraction (HF-rEF) using conservative (reaching target dose over 6 weeks) and condensed…
- Trial name
- TITRATION (NCT01922089)
- Testing
- LCZ696
- Where
- 105 sites in United States, Bulgaria and 9 more
- Volunteers
- 498 people
- Sponsor
- Novartis Pharmaceuticals
Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary
ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
The purpose of this study was to evaluate the safety and efficacy of revusiran (ALN-TTRSC) in patients with transthyretin (TTR) mediated Familial Amyloidotic Cardiomyopathy.
- Conditions
- Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Amyloid Neuropathies
- Trial name
- NCT02319005
- Testing
- Revusiran (ALN-TTRSC), Sterile Normal Saline (0.9% NaCl)
- Where
- 61 sites in United States, Belgium and 7 more
- Volunteers
- 206 people
- Sponsor
- Alnylam Pharmaceuticals
Cardiorenal Syndrome (CRS)
CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function
To advance our understanding of the mechanisms of human cardiorenal syndrome with emphasis upon the interaction of diuretic therapy and the renal-angiotensin-aldosterone -system and cGMP pathway.
- Trial name
- NCT01678794
- Testing
- Candesartan
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Mayo Clinic
Heart Failure, Type 2 Diabetes Mellitus
Ketones, Muscle Metabolism, and SGLT2 Inhibitors - Protocol 1
To examine the effect of an increase in plasma beta-hydroxy-butyrate (B-OH-B) levels, spanning the physiologic and pharmacologic range (+0.5, +2.0, and +5.0 mmol/L), on: (i) parameters of left ventricular (LV) systolic and…
- Trial name
- Protocol1 (NCT03560323)
- Testing
- Beta-hydroxy-butyrate
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Hypertension, Pulmonary
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF.
- Trial name
- CADENCE (NCT04945460)
- Testing
- Sotatercept 0.3 mg/kg, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
- Where
- 119 sites in United States, Belgium and 10 more
- Volunteers
- 165 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Diastolic Heart Failure
High Intensity Interval Exercise in Diastolic Heart Failure
Heart failure is a major health concern and is the leading cause of hospitalization among elderly Americans. Currently 5.7 million Americans are estimated to have heart failure and the estimated direct and indirect costs of…
- Trial name
- NCT02147613
- Testing
- High intensity interval training, Moderate intensity exercise training
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Arizona State University
Sinus Node Disease, AV Block
Ingenio Device Algorithm Study
The purpose of the IVORY Study is to gather data to support global submissions/approvals for some models of the Ingenio device family.
- Conditions
- Sinus Node Disease, AV Block, Heart Failure
- Trial name
- IVORY (NCT01441583)
- Testing
- RAAT, RYTHMIQ
- Where
- 21 sites in Austria, Belgium and 10 more
- Volunteers
- 139 people
- Sponsor
- Boston Scientific Corporation
Left Sided Heart Failure
HW006 LATERAL Thoracotomy
This is a prospective, multi-center,single-arm study that will evaluate the thoracotomy implant technique in up to 145 subjects implanted via thoracotomy with the HeartWare HVAD System and enrolled in the Interagency Registry for…
- Trial name
- HVAD (NCT02268942)
- Testing
- HeartWare HVAD, Thoracotomy
- Where
- 26 sites in United States, Canada
- Volunteers
- 144 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure
Clinical Hemodynamic Study of Balloon Counterpulsation in Advanced Heart Failure
The primary objective of this study is to develop normative hemodynamic data (means and standard deviations) for the intra-aortic balloon pump (IABP) using pressure-volume loop and 3D-echocardiographic analyses.
- Trial name
- NCT03001674
- Testing
- Conductance catheterization
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Tufts Medical Center
Acute Myocardial Infarction
Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial Infarction
Acute myocardial infarction is characterized by an intense inflammatory response. The degree of the response influences clinical outcome, with 'more' inflammation promoting heart failure.
- Trial name
- VCU-Alpha1RT (NCT01936896)
- Testing
- Alpha 1-Antitrypsin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Virginia Commonwealth University
Acute Heart Failure (AHF)
Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients
This was a multinational, multicenter, randomized, open-label study to confirm and expand the efficacy, safety and tolerability evidence of 48 hours intravenous infusion of serelaxin (30 micrograms/kg/day) when added to Standard…
- Trial name
- RELAX-AHF-EU (NCT02064868)
- Testing
- Serelaxin, Standard of Care
- Where
- 357 sites in Austria, Belgium and 23 more
- Volunteers
- 2,666 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)
This research study will test whether atorvastatin, a drug commonly prescribed for reducing cholesterol levels, can protect the heart during chemotherapy with doxorubicin.
- Trial name
- NCT02943590
- Testing
- Atorvastatin
- Where
- 4 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Massachusetts General Hospital
Heart Failure
A First Time in Human (FTIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK3884464 in Healthy Participants
This will be a FTIH study which aims to evaluate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and repeat oral doses of GSK3884464 administered to healthy participants.
- Trial name
- NCT05044325
- Testing
- GSK3884464
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Heart Failure
Assessing the Safety/Efficacy of Transdermal Testosterone in Female Patients With Symptomatic Heart Failure
Heart failure (HF) is a complex condition resulting from structural or functional heart diseases that impair the ability of the heart to fill with or pump out blood.
- Trial name
- CORDELIA (NCT00957034)
- Testing
- testosterone
- Where
- 16 sites in United States
- Volunteers
- 17 people
- Sponsor
- Warner Chilcott
Heart Failure, Arrhythmias, Cardiac
Heart Failure and Sudden Cardiac Death Japan Registry
The purpose of this observational registry is to collect clinical events and outcome data in 4 different study populations (cohorts), with a majority of Japanese subjects, that are at risk of sudden cardiac death (SCD) and heart…
- Conditions
- Heart Failure, Arrhythmias, Cardiac, Sudden Cardiac Death
- Trial name
- HINODE (NCT03185832)
- Testing
- CRT-D, ICD, PM / CRT-P
- Where
- 34 sites in Japan
- Volunteers
- 354 people
- Sponsor
- Boston Scientific Corporation
Dilated Cardiomyopathy, Lamin A/C Gene Mutation
A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation
This is a randomized, double-blind, placebo-controlled study in patients with dilated cardiomyopathy (DCM) due to a mutation of the gene encoding the lamin A/C protein (LMNA).
- Trial name
- REALM-DCM (NCT03439514)
- Testing
- ARRY-371797 (PF-07265803)
- Where
- 107 sites in United States, Argentina and 8 more
- Volunteers
- 77 people
- Sponsor
- Pfizer
Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
IVR-Enhanced Care Transition Support for Complex Patients
For complex medical patients, the transition from hospital to home-based care is a vulnerable period, placing the patient at high risk for adverse events.
- Trial name
- NCT01135381
- Testing
- IVR-Enhanced Care
- Where
- United States
- Volunteers
- 511 people
- Sponsor
- University of Alabama at Birmingham
Bradycardia, Heart Failure
ECG Belt to Assess Electrical Synchronization
The objective of the study is to assess the utility of ECG Belt to understand the conduction and ECG characteristics of Left Bundle Branch Pacing (LBBAP) and His-Optimized Cardiac Resynchronization Therapy (HOT-CRT) and compare…
- Trial name
- NCT04583709
- Testing
- ECG Belt
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Pugazhendhi Vijayaraman